Figure 6
Delayed fostamatinib treatment reduces levels of DSA IgG in sensitised rats. T lymphocyte crossmatch analysis was performed to detect DSA levels in sensitized fostamatinib and vehicle treated LEW rats. Treatment initiation was delayed until 7 days post-transfusion. (A) IgM levels remained the same in both treatment groups. (B) Circulating allogenic IgG levels were significantly lower in fostamatinib treated rats at days 14, 17 and 21 post-transfusion. (C) From 17 days onwards IgG1 levels were significantly lower in fostamatinib treated animals, from 14 days onwards IgG2a (D) levels were significantly lower in fostamatinib treated animals, and by 21 days post-transfusion IgG2b (E) levels were significantly lower in fostamatinib treated animals. No differences were observed in IgG2c levels at any measured time point (F) (n = 6 rats/group) *P ≤ 0.05, **P ≤ 0.01, ***P ≤ 0.001). Blue filled circle—vehicle, red filled triangle—fostamatinib.
